SCHEMBL4335988

SCHEMBL4335988

COc1ccnc(CN[C]=O)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.39
MTNR1B P49286 3/20 0.39
HTR1A P08908 1/20 0.36
TNKS O95271 1/20 0.35
PARP1 P09874 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
KLKB1 P03952 1/20 0.35
LOX P28300 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
NUDT1 P36639 1/20 0.32
OPRM1 P35372 1/20 0.31
OPRL1 P41146 1/20 0.31
GRM5 P41594 1/20 0.31
SYK P43405 1/20 0.31
MAT2A P31153 1/20 0.30
ENPP1 P22413 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25539772 0.80 MTNR1A (0.39) MTNR1AMTNR1BHTR1ATNKSPARP1
SCHEMBL4335990 0.77 HTR1A (0.41) MTNR1AMTNR1BHTR1ATNKSPARP1
SCHEMBL19127316 0.76 MTNR1A (0.57) MTNR1AMTNR1BHTR1AKLKB1
SCHEMBL22574533 0.76 MTNR1A (0.47) MTNR1AMTNR1BHTR1AKLKB1PDE1A
SCHEMBL30781992 0.75 MTNR1A (0.46) MTNR1AMTNR1BHTR1AKLKB1OPRM1
SCHEMBL19151203 0.74 MTNR1A (0.45) MTNR1AMTNR1BHTR1AKLKB1OPRM1
SCHEMBL2632841 0.73 TAAR1 (0.41) MTNR1AMTNR1BTNKSPARP1TNKS2
SCHEMBL24759680 0.72 MTNR1A (0.46) MTNR1AMTNR1BHTR1ASYKENPP1
SCHEMBL10332669 0.72 LOX (0.39) MTNR1AMTNR1BHTR1ATNKSPARP1
SCHEMBL23512140 0.72 HPGD (0.44) MTNR1AMTNR1BHTR1AKLKB1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2042502-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2009-04-01 EP disclosed
EP-1544199-B1 NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC (JP) 2008-10-15 EP disclosed
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2008-07-03 US disclosed
US-7211572-B2 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed
US-20060052361-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2006-03-09 US disclosed
EP-1544199-A1 NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC. (JP) 2005-06-22 EP disclosed
US-20050054645-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054645-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor NNMT, PNP, DNTT MTNR1A 4711/4885MTNR1B 4487/4885HTR1A 4267/4885
US-20060052361-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor NNMT, PNP, DNTT MTNR1A 4711/4885MTNR1B 4487/4885HTR1A 4267/4885
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor DNTT, PNP, NNMT MTNR1A 4563/4885MTNR1B 4510/4885HTR1A 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.